A case report published in Sage Journals documents a dog with lymphoma affecting both the mediastinal and retroperitoneal regions in which tumor cells expressed neither T-cell nor B-cell surface antigens — a presentation that defies the standard immunophenotyping framework used in small-animal oncology.

The report, carried under the title "Diagnostic challenge in veterinary pathology: Mediastinal and retroperitoneal lymphoma without T/B surface antigen expression in a dog," centers on a diagnostic problem that clinicians increasingly encounter as flow cytometry and immunohistochemistry become routine in lymphoma workups. The anatomic distribution itself is unusual: mediastinal and retroperitoneal involvement in the same patient points to a disease process that crosses body cavities, complicating both staging and therapeutic planning.

Why does the missing antigen expression matter?

Canine lymphoma classification depends heavily on assigning tumors to a T-cell or B-cell lineage. That assignment drives prognosis and, in many protocols, drug selection. When malignant lymphocytes carry neither lineage's surface markers, pathologists cannot place the tumor in the standard categories, and the attending veterinarian loses the prognostic anchor that immunophenotype normally supplies.

Null-cell — or antigen-negative — lymphoma is recognized in human pathology but remains sparsely documented in veterinary medicine. Each published case adds a data point to a literature thin enough that individual reports still shape how practitioners interpret equivocal flow cytometry results.

What happens at the exam table?

For clinicians, the case underscores a practical point: a negative immunophenotyping panel does not exclude lymphoma. When cytology or histology shows malignant lymphocytes but marker studies come back empty, the diagnosis stands on morphology and clinical context, not on antigen confirmation. Practitioners should expect longer diagnostic timelines in such cases and should communicate that uncertainty to owners before committing to a protocol built around phenotype-specific prognoses.

The combined mediastinal and retroperitoneal location also raises imaging considerations. Disease spanning two compartments typically warrants full-body imaging — computed tomography or a comparable modality — to establish extent before treatment begins, rather than relying on regional radiographs alone.

How does this fit the broader pathology picture?

Case reports of this kind serve a function larger than a single patient. They alert diagnostic laboratories to patterns that automated or panel-based reporting may miss, and they give pathologists cited precedent when they sign out similar specimens. The Sage Journals publication joins a small body of veterinary literature documenting antigen-negative lymphoma in dogs, a literature that — unlike the well-mapped T- and B-cell categories — still lacks the case numbers needed for firm incidence estimates or outcome benchmarks.

For the companion-animal sphere, the implications are direct: oncologists and general practitioners alike may face these null-phenotype cases, and the absence of lineage markers should trigger consultation with a diagnostic pathology service rather than an assumption of sampling error. No food-animal or public-health dimension attaches to this finding; the significance is confined to small-animal diagnostics and oncology.

The report's publication suggests diagnostic laboratories and referring veterinarians will encounter — and must now formally account for — lymphoma variants that sit outside the conventional T/B dichotomy, an accounting that will sharpen as additional cases accumulate in the veterinary literature.